Break Free Women's Gynecology Catalog 2021
She overcome everything that was meant to destroy her

Women are the largest demographic and the most powerful voice in the developed world. Yet women are still debilitated by the same conditions that affected their mothers, limiting them to live to their full potential, to be the wives, mothers, teachers, businesswomen that they aspire to be.

The world cannot afford this any longer.

We are committed to giving women treatments that can transform their lives. We design medications just for women, that just so happen to be well researched....and work well.

Our therapies bring peace of mind to our patients, helping them break free from worry and reach their full potential - to lead fuller, healthier lives.

Women need help.
Help them break free.
Freedom to move


Vaginal Pain

Burning, stabbing, throbbing pain. Vulvodynia is often debilitating, regularly making patients choose only activities that can be tolerated, managing the amount of time they sit each day, fearing constantly that they will never be able to live without the pain.

Clinical evidence

In a case study of a 33-year-old woman who had “intractable chronic vulvar and anal pain and had to abstain from sexual intercourse and could neither cycle nor sit for more than 5 minutes,” the patient did not respond to standard treatments. After a 3 month treatment of a combination of topical baclofen 5% and palmitoylethanolamide 400 mg, three times daily, her symptoms decreased more than 50% and sexual intercourse was possible again without pain.

BACLOFEN vaginal cream

strength: baclofen 5% cream
dosing: 0.5 to 1 gm PV TID

PMAE tablets

strength: 600mg tablets
dosing: 1 tablet PO BID

Freedom to explore


Lack of Urinary Control

Patients suffer unnecessarily with incontinence, scouting for a restroom within 20 feet in public spaces. Conversations are distracted, clouded by thoughts of shame due to possible incidents that might occur right now.

Clinical evidence

In a study of 60 postmenopausal women, estriol 0.5mg was administered intravaginally 3 times a week. The results of the study showed complete remission of urinary incontinence in 1/3 of the women and another 1/3 of the women studied showed a 75% improvement in urinary retention.

ESTRIOL vaginal cream

strengths: 0.5 to 10 mg/gm
dosing: 0.5gm PV QHS
clinically studied dose: 0.5mg PV QHS

Freedom to explore


Painful Vaginal Sex


In 2 clinical studies with a patient population of more than 60 women each, at least 65% of patients reported relief of dyspareunia and soreness after a treatment duration of 4 to 7 weeks.


A phase III study of 154 postmenopausal women with dyspareunia showed 115% improvement in lubrication,and a 108% improvement in pain.

OXYTOCIN vaginal gel

strength: 400IU/gm
dosing: 1 gm PV QD

DHEA vaginal cream

strength: 10mg/gm
dosing: 0.5 to 1gm PV QD

Freedom to relax


Vaginal Yeast Infection

Like clockwork, patients suffer vaginal infection after infection after infection for what seems like no apparent reason. On top of being tested regularly for STDs, they have tried everything, from antibiotics, antifungals, and odor control suppositories. Patients are often bogged down by vaginal itching and burning sensations, keeping them from living their daily life.

Clinical evidence

In a double-blind comparison of boric acid 600mg vs nystatin 100,000 units, cure rates for boric acid was 92% at 7 to 10 days after treatment versus nystatin cure rates at 64%. At 30 days, boric acid maintained a 72% cure rate versus 50% for nystatin.

BORIC ACID capsules

strength: 600mg
doosing: 1 cap PV QHS x 14 days

Freedom to be a women


Polycystic Ovarian Syndrome

PCOS diagnoses usually don’t manifest until later in life, usually after a long struggle with acne, weight gain, and excel facial hair that can expand everywhere on their face, creating a “man beard.” This means that shaving, plucking, trimming, waxing, or bleaching will not, cannot, fix the problem. It only makes it worse.

As early as in their 20s, patients worry about their risk of developing Type II diabetes and their inability to carry a child in the future. These risks are real: about 50% of women diagnosed with PCOS will become diabetic by the age of 40.

Clinical evidence

In a clinical study of 186 anovulatory women secondary to PCOS, recovery of reproductive abnormalities was achieved with a range of 59.7% to 80% across all 4 phenotypes with a combination treatment of myoinositol, L- tyrosine, folic acid, selenium, and chromium. Other improvements noted throughout the treatment were decreased androgen levels, improved insulin levels and glucose homeostasis, and improvements in BMI.


strength: 2000mg myoinositol + 0.5mg L-tyrosine + 0.2mg folic acid + 55mcg selenium + 40mcg chromium
dosing: 4 capsules PO QD for 6 months

pcos suppress capsules


  1. Keppel Hesselink JM, Kopsky DJ, Sajben NL. Vulvodynia and proctodynia treated with topical baclofen 5% and palmitoylethanolamide. Arch Gynecol Obstet. 2014;290(2):389–393.
  2. Nyirjesy, Paul MD1; Lev-Sagie, Ahinoam MD2; Mathew, Leny MS1; Culhane, Jennifer F. PhD. Topical Amitriptyline-Baclofen Cream for the Treatment of Provoked Vestibulodynia. J. Lower Urinary Tract Disease. 2009;13(4):230-236.
  3. Keppel Hesselink JM, Kopsky DJ, Sajben NL. Vulvodynia and proctodynia treated with topical baclofen 5% and palmitoylethanolamide. Arch Gynecol Obstet. 2014;290(2):389–393.
  4. Kopsky DJ, Keppel Hesselink JM. Neuropathic pain as a result of acromegaly, treated with topical baclofen cream. J Pain Symptom Manage. 2013;46(4):e4–e5
  5. Lo Verme, J.; Fu, J.; Astarita, G.; La Rana, G.; Russo, R.; Calignano, A.; Piomelli, D. (2005). "The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide". Molecular Pharmacology. 67 (1): 15–19.
  6. Keppel Hesselink, J.M. 2012. New Targets in Pain, Non-Neuronal Cells, and the Role of Palmitoylethanolamide. Open Pain Journal 5: 12-23
  7. Keppel Hesselink, J.M., Hekker, T.A. 2012. Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series Journal of Pain Research 5:437 – 442
  1. Keppel Hesselink JM. Chronic idiopathic axonal neuropathy and pain, treated with the endogenous lipid mediator palmitoylethanolamide: a case collection. International Medical Case Reports Journal Published Date September 2013 Volume 2013:6 Pages 49 – 53
  2. Caruso S, Cianci A, Sarpietro G, Matarazzo MG, Panella M, Cianci S. Ultralow 0.03 mg vaginal estriol in postmenopausal women who underwent surgical treatment for stress urinary incontinence: effects on quality of life and sexual function. Menopause. 2020;27(2):162‐169.
  3. Schulte-Uebbing C, Schlett S, Craiut D, Bumbu G. Stage I and II Stress Incontinence (SIC): High dosed vitamin D may improve effects of local estriol. Dermatoendocrinol. 2016;8(1):e1079359. Published 2016 Apr 19.
  4. Al-Saqi SH, Uvnäs-Moberg K, Jonasson AF. Intravaginally applied oxytocin improves post-menopausal vaginal atrophy. Post Reprod Health. 2015;21(3):88‐97. doi:10.1177/2053369115577328
  5. Jonasson AF, Edwall L, Uvnäs-Moberg K. Topical oxytocin reverses vaginal atrophy in postmenopausal women: a double-blind randomized pilot study. Menopause Int. 2011;17(4):120‐125. doi:10.1258/mi.2011.011030
  6. Torky, H etal. Role of topical oxytocin in improving vaginal atrophy in postmenopausal women: a randomized, controlled trial. Climacteric. 2018 Apr;21(2):174-178
  1. Keller Van Slyke K, Michel VP, Rein MF. Treatment of vulvovaginal candidiasis with boric acid powder. Am J ObsGyne. 1981;141:145–8
  2. Swate TE, Weed JC. Boric acid treatment of vulvovaginal candidiasis. ObsGyne. 1974;43:893–5.
  3. Jovanovic R, Congema E, Nguyen HT. Antifungal agents vs boric acid for treating chronic mycoticvulvovaginitis. J Reprod Med. 1991;36:593–7.
  4. Sobel JD, Chaim W. Treatment of Torulopsisglabrata vaginitis: retrospective review of boric acid therapy. ClinInf Dis. 1997;24:649–52. doi: 10.1093/clind/24.4.649.
  5. Guaschino S, De Seta F, Sartore A, Ricci G, De Santo D, Piccoli M, Alberico S. Efficacy of maintenance therapy with topical boric acid in comparison with oral itraconazole in the treatment of recurrent vulvovaginal candidiasis. Am J ObsGyne. 2001;184:598–602.
  6. Reichman O, Akins R, Sobel JD. Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis. Sex Transm Dis. 2009;36(11):732–4.
  7. Montanono Oliva M, etal. Efficacy of the synergistic action of myoinositol, tyrosine, selenium and chromium in women with PCOS. Eur Rev Med Pharmacol Sci. 2019 Oct;23(19):8687-8694
She deserves the best

Harbor Science, powered by Harbor Compounding Pharmacy generates only high quality, efficacious formulations, researched and developed for enhanced drug delivery and optimal results. To learn more about the Harbor Science product line, go to
or email

Harbor Compounding Pharmacy